A

    Amphastar P (AMPH)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $22.53
    +0.52 (+2.36%)

    Market Cap: $936.26M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    78%(31/40)
    Avg Surprise
    +41.42%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$0.86
    Range$0.70 - $1.05
    7 analysts
    EPS Revisions
    2
    0
    7d
    1
    3
    30d
    EPS Estimate Drift
    90d ago$0.83-4.4%
    60d ago$0.81-5.8%
    30d ago$0.79-8.5%
    7d ago$0.85-1.5%
    Current$0.86
    Revenue Consensus
    $198M
    Range$184M - $207M
    6 analysts
    Dec 31, 2026
    EPS Consensus$0.79
    Range$0.41 - $1.06
    7 analysts
    Revenue Consensus
    $197M
    Range$160M - $215M
    6 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.79---
    Sep 26EST
    		-$0.86---
    Jun 26
    		$0.80$0.51+56.86%Beat+6.7%
    Mar 26
    		$0.42$0.71-40.85%Miss-43.2%
    Dec 25
    		$0.61$0.89-31.46%Miss-33.7%
    Sep 25
    		$0.93$0.83+12.05%Beat-3.1%
    Jun 25
    		$0.75$0.64+17.19%Beat-20.2%
    Mar 25
    		$0.74$0.69+7.25%Beat-28.8%
    Dec 24
    		$0.92$0.94-1.95%Miss+4.5%
    Sep 24
    		$0.96$0.98-2.04%Miss-16.5%
    Jun 24
    		$0.94$0.75+25.33%Beat+44.6%
    Mar 24
    		$1.04$0.79+31.65%Beat+67.7%
    Dec 23
    		$0.88$0.91-3.30%Miss+20.5%
    Sep 23
    		$1.15$0.69+66.67%Beat+202.6%
    Jun 23
    		$0.65$0.56+16.07%Beat+66.7%
    Mar 23
    		$0.62$0.50+24.00%Beat+31.9%
    Dec 22
    		$0.73$0.41+78.05%Beat+73.8%
    Sep 22
    		$0.38$0.39-2.56%Miss-17.4%
    Jun 22
    		$0.39$0.35+11.43%Beat+85.7%
    Mar 22
    		$0.47$0.36+30.56%Beat+74.1%
    Dec 21
    		$0.42$0.36+16.67%Beat+162.5%
    Sep 21
    		$0.46$0.23+100.00%Beat+206.7%
    Jun 21
    		$0.21$0.21+0.00%Beat+31.2%
    Mar 21
    		$0.27$0.18+50.00%Beat+58.8%
    Dec 20
    		$0.16$0.14+14.29%Beat+128.6%
    Sep 20
    		$0.15$0.14+7.14%Beat+50.0%
    Jun 20
    		$0.16$0.14+14.29%Beat+100.0%
    Mar 20
    		$0.17$0.09+88.89%Beat+70.0%
    Dec 19
    		$0.07$0.08-12.50%Miss-46.2%
    Sep 19
    		$0.10$0.07+42.86%Beat-16.7%
    Jun 19
    		$0.08$0.05+60.00%Beat+166.7%
    Mar 19
    		$0.10$0.05+100.00%Beat+300.0%
    Dec 18
    		$0.13$0.11+18.18%Beat+30.0%
    Sep 18
    		$0.12$0.11+9.09%Beat+71.4%
    Jun 18
    		$0.03N/A-62.50%Miss-72.7%
    Mar 18
    		$-0.05$0.08-162.50%Miss-155.6%
    Dec 17
    		$0.10$-0.02+600.00%Beat+900.0%
    Sep 17
    		$0.07$0.03+133.33%Beat-50.0%
    Jun 17
    		$0.11$0.07+57.14%Beat-
    Mar 17
    		$0.09$0.08+12.50%Beat-
    Dec 16
    		$0.01$-0.01+200.00%Beat-
    Sep 16
    		$0.14$0.08+75.00%Beat-

    Key Metrics

    Valuation
    P/E Ratio8.16EV/EBITDA6.89x
    Price/FCF6.43xFCF Yield15.55%
    Profitability
    Profit Margin10.80%Operating Margin21.60%
    ROE10.30%ROIC6.63%
    Financial Health
    Debt/Equity0.80xInterest Coverage4.55x
    Current Ratio2.40xQuick Ratio1.71x
    Trading Statistics
    Beta0.90Avg Volume437.33K
    52-Week High$31.2652-Week Low$16.64

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$21.83
    SMA 20$21.08
    SMA 50$20.28
    SMA 200$22.58
    EMA 10$21.77
    EMA 20$21.26
    EMA 50$20.61
    EMA 200$22.02

    MACD

    Line: 0.61Signal: 0.50Hist: 0.11

    ADX

    ADX: 28.8+DI: 34.2-DI: 11.5

    Aroon & PSAR

    Aroon Up100.0
    Aroon DownN/A
    PSAR$19.78

    Bollinger Bands

    Upper Band$22.77
    Lower Band$19.40
    %B Position1602%(Upper)
    Band Width0.93

    RSI (14-Day)

    Neutral
    68.3

    Momentum Oscillators

    Stoch %K87.3
    Stoch %D82.9
    Williams %R-3.9
    ROC (10d)8.0%
    Momentum1.67
    CCI (20d)107.3
    MFI (14d)76.6

    Volatility Measures

    ATR (14d)$0.76(3.4%)
    StdDev (20d)0.84
    Hist Vol30.9%(Moderate)

    Volume Flow

    VWAP$22.23
    OBV2.5M
    AD Line-5.9M
    CMF (20d)0.022

    Volume Metrics

    Avg Vol (20d)438.5K
    Vol Ratio0.6x
    VWMA (20d)$20.91

    Pivot Points

    R3$22.67
    R2$22.41
    R1$22.21
    Pivot Point$21.95
    S1$21.75
    S2$21.49
    S3$21.29

    Advanced Oscillators

    TSI24.48
    Ultimate Osc61.9
    KST93.32

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$183.90M$171.17M$183.10M$191.84M$174.41M$170.53M$186.52M$191.21M$182.39M$171.84M$178.10M$180.56M
    Cost of Revenue$90.43M$100.85M$97.44M$93.19M$87.92M$85.28M$99.88M$89.27M$87.23M$81.74M$81.97M$72.15M
    Gross Profit$93.47M$70.32M$85.67M$98.65M$86.49M$85.25M$86.65M$101.94M$95.17M$90.10M$96.14M$108.40M
    Operating Expenses$53.74M$56.69M$50.06M$73.33M$44.31M$47.96M$41.50M$44.89M$39.95M$42.09M$42.16M$35.73M
    R&D$22.16M$26.74M$23.31M$22.35M$20.08M$20.10M$18.14M$21.08M$17.65M$17.04M$20.42M$16.66M
    SG&A$18.24M$18.03M$16.47M$39.47M$13.99M$16.00M$12.94M$14.82M$13.29M$15.68M$13.12M$12.65M
    Operating Income$39.73M$13.63M$35.61M$25.32M$42.18M$37.29M$45.14M$57.05M$55.22M$48.01M$53.98M$72.68M
    Interest Income$2.29M$2.40M$2.42M$2.25M$1.92M$2.09M$2.29M$2.43M$3.34M$2.56M$2.30M$1.20M
    Interest Expense$6.66M$6.55M$6.63M$6.28M$6.28M$6.29M$6.42M$6.70M$8.61M$8.61M$9.46M$13.70M
    Income Before Tax$38.54M$10.05M$31.91M$21.51M$39.34M$30.86M$43.96M$47.68M$50.24M$47.88M$41.34M$63.64M
    Income Tax Expense$8.20M$3.63M$7.49M$4.16M$8.30M$5.58M$6.00M$7.25M$12.29M$4.13M$4.67M$14.03M
    Net Income$30.35M$6.42M$24.43M$17.35M$31.03M$25.29M$37.96M$40.43M$37.95M$43.18M$36.17M$49.22M
    EBITDA$60.25M$31.46M$52.97M$42.20M$60.78M$51.03M$63.48M$67.13M$72.10M$70.02M$65.20M$94.94M
    EBIT$42.92M$14.21M$36.12M$25.55M$43.70M$35.06M$48.09M$51.95M$55.52M$53.93M$48.50M$76.14M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about AMPH

    News

    Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for

    Amphastar Pharmaceuticals (AMPH) is projected to report a year-over-year decline in earnings for the quarter ended June 2026, despite an expected increase in revenues. Analysts have recently become more bearish on the company's earnings prospects, leading to a negative Earnings ESP and a Zacks Rank of #5, making an earnings beat difficult to predict. Investors are advised to consider other factors beyond just an earnings beat or miss, and Supernus Pharmaceuticals (SUPN) is highlighted as a stronger earnings-beat candidate within the same industry.

    Eastern Progress•8/22/26•
    Somewhat-Bearish

    Enterprise value to EBITDA forward of Amphastar Pharmaceuticals, Inc. – NASDAQ:AMPH

    The article focuses on the enterprise value to EBITDA forward metric for Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH). It appears to be a financial data page from TradingView, providing an overview of the company's financial performance.

    TradingView•8/22/26•
    Neutral

    Denali Advisors LLC Has $7.59 Million Position in Amphastar Pharmaceuticals, Inc. $AMPH

    Denali Advisors LLC significantly increased its stake in Amphastar Pharmaceuticals (NASDAQ:AMPH) by 41.1% in Q2, bringing its total holdings to 375,965 shares valued at $7.59 million. Despite Amphastar exceeding Q2 earnings expectations with $0.91 EPS against a $0.62 consensus, analyst sentiment remains cautious, with a "Reduce" rating and a $22.50 price target. This comes amidst insider share sales and institutional investors collectively owning a majority of the company's stock.

    MarketBeat•8/20/26•
    Somewhat-Bearish

    Barclays Issues Positive Forecast for Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Price

    Barclays has increased its price target for Amphastar Pharmaceuticals (NASDAQ:AMPH) from $20 to $23, maintaining an "equal weight" rating and suggesting a 7.1% upside. Despite this, analyst sentiment remains cautious with a MarketBeat consensus rating of "Reduce" and an average target of $22.50. The company recently surpassed quarterly expectations, reporting $0.91 EPS against a $0.62 estimate and revenue of $183.9 million, exceeding the $179.9 million forecast.

    MarketBeat•8/19/26•
    Neutral

    Amphastar (NASDAQ: AMPH) insider lines up stock sale after option exercise

    Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) insider Floyd Petersen plans to sell 47,101 shares of common stock, valued at $989,121, through UBS Financial Services Inc. This sale is being executed under Rule 144, following an option exercise for cash on August 18, 2026, which is also the proposed sale date. The transaction represents a small fraction of the 44,092,000 shares outstanding.

    Stock Titan•8/18/26•
    Somewhat-Bearish

    Frequently Asked Questions About AMPH

    Does AMPH pay dividends?
    Amphastar P (AMPH) does not currently pay a regular dividend.
    What is AMPH's P/E ratio?
    Amphastar P has a price-to-earnings (P/E) ratio of 8.16.
    What is AMPH's market cap?
    Amphastar P (AMPH) has a market capitalization of $936.26M with a current stock price of $22.53.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In